MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

MSD's Gardasil®9, a nine-valent HPV vaccine, is approved for use in males between 16 and 26 years old by China's National Medical Products Administration on Monday. [Photo provided to chinadaily ...

Gardasil 9. "MSD’s HPV vaccine gains China NMPA’s expanded approval for males" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on ...

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...